BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals Inc. (Nasdaq:KERX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/KERX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Keryx Biopharmaceuticals Inc. (KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases including renal disease and cancer. The Company is developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is in phase II clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). KERX is developing KRX-0401 (perifosine), oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 is in phase II clinical development for multiple tumor types.
In the report, the analyst notes:
"KERX and AEterna Zentaris recently announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation for perifosine, a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer. Fast Track designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process ...
"According to the report, a randomized, double-blind phase III trial investigating perifosine in combination with capecitabine (Xeloda®) versus placebo in combination with capecitabine (Xeloda®) in patients with refractory metastatic colorectal cancer is expected to commence this quarter under a Special Protocol Assessment (SPA) with the FDA."
SOURCE Beacon Equity Research/td>